Sudocetaxel zendusortide is under clinical development by Theratechnologies and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sudocetaxel zendusortide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sudocetaxel zendusortide overview
TH-1902 is under development for the treatment of triple-negative breast cancer, epithelial ovarian cancer, colorectal cancer, pancreatic cancer, endometrial cancer, lung cancer, thyroid cancer, small-cell lung cancer, prostate cancer, peritoneal cancer and melanoma. The therapeutic candidate comprises of docetaxel conjugated to a peptide (the docetaxel-TH19P01peptide conjugate (TH1902). It is developed based on SORT1 plus Technology. It acts by targeting cells expressing sortilin. It is administered through intravenous route.
Theratechnologies overview
Theratechnologies is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, CD-4 directed post-attachment HIV-1 inhibitor indicated for HIV type 1 infection in the US. Its pipeline products include Trogarzo IV slow push for HIV and Egrifta F8 for NASH HIV. The company is also developing TH 1902 for triple-negative breast cancer and TH1904 for ovarian cancer. It develops products based on peptide stabilization technology to increase target protein resistance to enzymatic degradation. Theratechnologies is headquartered in Montreal, Quebec, Canada.
For a complete picture of Sudocetaxel zendusortide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
